Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study.
Kerstin N VokingerCamille E G GlausAaron S KesselheimMiquel Serra-BurrielJoseph S RossThomas J HwangPublished in: BMJ (Clinical research ed.) (2023)
The proportion of supplemental indications rated as having high therapeutic value was substantially lower than for first indications. When first or supplemental indications do not offer added therapeutic value over other available treatments, that information should be clearly communicated to patients and physicians and reflected in the price of the drugs.